News - Page 7 of 7 - HanchorBio

HANCHORBIO ANNOUNCES US FDA CLEARANCE OF IND APPLICATION FOR HCB301 TRI-SPECIFIC FUSION PROTEIN TO TREAT SOLID AND HEMATOLOGICAL MALIGNANCIES

HanchorBio Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s investigational new drug (IND) application to initiate a multi-regional clinical trial of its independently developed novel drug candidate, HCB301 today.HCB301-101 is a multiregional, multicenter, open-label, dose-finding, first-in-human (FIH) study of adults with advanced solid tumors or relapsed and refractory classical Hodgkin lymphomas in the US, Australia, and Taiwan. The study evaluates the safety, tolerability, pharmacokinetics, and preliminary clinical efficacy of weekly HCB301 intravenous injections. The HCB301 IND is on track to be reviewed by the Australia Therapeutic Goods Administration (TGA) and the Taiwan FDA.

Jun 28, 2024

The Chairman/CEO of HanchorBi Inc : Scott Liu is awarded as “30 Best CEOs of the Year 2024”

Our mission is to transcend immuno-oncology therapies by developing cutting-edge designer biologics with novel modalities: Dr. Scott Liu of HanchorBio Inc. “I envision that in five years, HanchorBio to be one of the leading biotech companies in immuno-oncology in the world through the development of safe and efficacious cutting-edge designer biologics with novel modalities.” […]

Feb 26, 2024

HANCHORBIO ANNOUNCES TAIWAN FDA IND APPROVAL FOR THE MULTI-REGIONAL CLINICAL TRIAL OF HCB101 TO TREAT SOLID AND HEMATOLOGICAL MALIGNANCIES

HanchorBio Inc., a global clinical-stage biotechnology company developing innovative immuno-biomedicines, announced today that the Taiwan Food and Drug Administration (TFDA) has approved its investigational new drug (IND) application to initiate a multi-regional clinical trial of its independently-developed novel drug candidate, HCB101, for the treatment of patients with advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma.

Jul 24, 2023

about HanchorBio Q&A

1.Why was HanchorBio founded? 2.When was HanchorBio established, and what is its founding mission?3. What research achievements or fundraising successes has HanchorBio accomplished so far? 4.What is HanchorBio’s vision? 5.In the fields of biotechnology and healthcare, what contributions can HanchorBio make to society? 6.What are the key differences and advantages between HanchorBio’s drug candidates and traditional therapies? What is the core technology? 7.What is FBDB™? What makes it special, and how does it support research and development? 8.What is the expected scale or extent of the beneficiaries? For such multi-target biologics designed to reactivate the immune system against diseases, can this mechanism be applied to other diseases or medical fields?

Apr 25, 2023

HANCHORBIO ANNOUNCES US IND CLEARANCE FOR THE MULTI-REGIONAL CLINICAL TRIAL OF HCB101 TO TREAT SOLID AND HEMATOLOGICAL MALIGNANCIES

HanchorBio Inc., a global clinical-stage biotechnology company developing innovative immuno-biomedicines, announced today that the US. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to initiate a multi-regional clinical trial of its independently-developed novel drug candidate, HCB101, for the treatment of patients with advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma.

Apr 17, 2023

HanchorBio Completes the Face-to-Face Scientific Advisory Board Meeting

HanchorBio Inc. completed a face-to-face Scientific Advisory Board (SAB) meeting on March 29, 2023, in Taipei, Taiwan withworld-renowned professors and few Board of Director (BOD) members.

Apr 13, 2023

HanchorBio Completes the Face-to-Face Scientific Advisory Board Meeting

HanchorBio Inc., a global clinical-stage biotechnology company developing innovative immuno-medicines, completed a face-to-face Scientific Advisory Board (SAB) meeting on March 29, 2023 in Taipei, Taiwan with world-renowned professors and few Board of Director (BOD) members.

Apr 11, 2023

HanchorBio Founder and Chief Executive Officer Dr. Scott Liu Receives Award from Chinese-American Biopharmaceutical Society

Dr. Liu was awarded on November 12, 2022, as part of the CABS 23rd Annual BioPacific Conference entitled, “Resilience and Ingenuity – Embracing Opportunities in a New Normal”. The theme this year reflects economic and supply chain turbulences that have presented both new challenges and opportunities for the life sciences and biopharmaceutical industries, despite ongoing COVID-19. For the past 24 years, CABS has been one of the largest and most active non-profit biopharmaceutical organizations in western United States.

Nov 12, 2022

HanchorBio Participated in Sino-American Pharmaceutical Professionals Association (SAPA) Annual Conference

At the SAPA conference, HanchorBio presented the company’s proprietary Fc-based designer biologics (FBDB™) platform led to biological products that targeting phagocytosis checkpoint blockade and incorporating both innate and adaptive immune responses to treat patients with cancer. During the conference, HanchorBio ended with dozens of one-on-one meetings with national and international partners and multiple possible leads for in-licensing, research collaborations, or commercial right out-licensing conducted by Dr. Yi Du (Sr. Director of Business Development). These discussions mainly focused on advancing science and innovation on the development of anti-tumor immunotherapies to eliminate tumor immune escape.

Oct 18, 2022

HANCHORBIO INC. ANNOUNCES CLOSING OF SERIES-A FINANCING

August 5th, 2022 – HanchorBio Inc. (“HanchorBio”), a biotechnology company pioneering the development of next-generation immunotherapies, today announced the successful completion of approximately US$20 million Series-A financing. The proceeds will enable HanchorBio to further expand and accelerate its growing pipeline of the proprietary Fc-based designer biologics (FBDB™) and to support the anticipated investigational new drug (IND)-enabling good laboratory practice (GLP) toxicology studies, IND submissions, and the first part of phase 1 clinical trials.

Aug 25, 2022